Iovance Biotherapeutics, Inc. - Common Stock (IOVA)
9.5600
-5.2500 (-35.45%)
NASDAQ · Last Trade: Oct 29th, 6:22 PM EDT
News & Press Releases
US Stock Market Movers: Top Gainers and Losers for the Sessionchartmill.com
Via Chartmill · October 29, 2026
These 2 Stocks Have Skyrocketed in 2026. Here’s Why I’d Stay Awayfool.com
These biotechs’ valuations are through the roof.
Via The Motley Fool · October 29, 2026
Iovance’s Lifileucel Shows 25% Lung Cancer Response Rate, Targets 2027 FDA Filingmarketbeat.com
Iovance Biotherapeutics (NASDAQ:IOVA) reported updated data from its registrational IOV-LUN-202 trial of lifileucel in previously treated, non-squamous metastatic non-small cell lung cancer, outlining plans for a supplemental Biologics License Application submission in 2027 and a new biomarker-enric
Via MarketBeat · October 29, 2026
Top US Stock Gainers and Losers for Oct. 29, 2026chartmill.com
Via Chartmill · October 29, 2026
Gap-Up and Gap-Down Stocks in the Oct. 29, 2026 Sessionchartmill.com
Via Chartmill · October 29, 2026
Premarket Gainers and Losers on Oct. 29, 2026chartmill.com
Via Chartmill · October 29, 2026
Iovance Reports Updated IOV-LUN-202 Results and Adds Precision TIL Strategy for Second-Line Metastatic Non-Small-Cell Lung Cancer (mNSCLC)
24.6% Objective Response Rate (ORR) in 69 Patients with Non-Squamous mNSCLC, Consistent with Previously Reported Results
By Iovance Biotherapeutics, Inc. · Via GlobeNewswire · October 29, 2026
Iovance Biotherapeutics to Host Webcast on Positive Data for TIL Therapy in Metastatic Non-Small Cell Lung Cancer (mNSCLC) and Broader Precision Medicine Strategy
Live Webcast at 8:30 a.m. ET on Thursday, October 29, 2026
By Iovance Biotherapeutics, Inc. · Via GlobeNewswire · October 28, 2026
Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026
PHILADELPHIA, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a conference call and live audio webcast on Thursday, November 5, 2026 at 8:30 a.m. ET to report its third quarter 2026 financial results and corporate updates.
By Iovance Biotherapeutics, Inc. · Via GlobeNewswire · October 27, 2026
Immuno-Oncology Emerges as a Major Force in the Global Cancer Treatment Market
EQNX::TICKER_START (NASDAQ:GTBP),(NASDAQ:MRNA),(NASDAQ:IOVA),(NASDAQ:GMAB),(NYSE:PFE) EQNX::TICKER_END
Via FinancialNewsMedia · October 26, 2026
Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026
50% Confirmed Objective Response Rate (ORR) with All Responses Ongoing in an Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2026
By Iovance Biotherapeutics, Inc. · Via GlobeNewswire · October 26, 2026
Iovance Presents New Data at ESMO 2026 Demonstrating Deep, Durable Responses with Lifileucel TIL Cell Therapy Plus Pembrolizumab in Frontline Advanced Melanoma
62.5% Confirmed Objective Response Rate (ORR) and 29.2% Complete Response (CR) Rate in Final Phase 2 Analysis
By Iovance Biotherapeutics, Inc. · Via GlobeNewswire · October 23, 2026
Iovance Highlights TIL Cell Therapy Platform Across Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2026
Iovance Advances TIL Cell Therapy into a New Chapter in Solid Tumor Treatment
By Iovance Biotherapeutics, Inc. · Via GlobeNewswire · October 19, 2026
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
PHILADELPHIA, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on October 15, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 111,615 shares of Iovance��s common stock to twenty-one new, non-executive employees.
By Iovance Biotherapeutics, Inc. · Via GlobeNewswire · October 16, 2026
Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
Leader in Global Drug Development of T Cell Therapies
By Iovance Biotherapeutics, Inc. · Via GlobeNewswire · October 1, 2026
Top movers analysis one hour before the close of the markets on 2026-09-29: top gainers and losers in today's session.chartmill.com
Via Chartmill · September 29, 2026
Most active stocks in Tuesday's sessionchartmill.com
Via Chartmill · September 29, 2026
These stocks are moving in today's sessionchartmill.com
Via Chartmill · September 29, 2026
Traders are paying attention to the gapping stocks in Tuesday's session.chartmill.com
Via Chartmill · September 29, 2026
Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million
New Guidance Represents an Increase of $55 Million at the Midpoint from the Prior Range of $350 to $370 Million
By Iovance Biotherapeutics, Inc. · Via GlobeNewswire · September 29, 2026
Why Iovance Biotherapeutics Stock Was on Fire Todayfool.com
An influential investment bank resumed its coverage of the company.
Via The Motley Fool · September 24, 2026
Iovance Maps TIL Therapy Expansion After Record Revenue and Margin Gainsmarketbeat.com
Iovance Biotherapeutics (NASDAQ:IOVA) said it is expanding its tumor-infiltrating lymphocyte, or TIL, therapy platform across multiple solid-tumor indications after reporting a record second quarter marked by nearly $100 million in revenue and a 56% margin.
Speaking at the H.C. Wainwright 28th Annu
Via MarketBeat · September 19, 2026
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on September 17, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 179,750 shares of Iovance’s common stock to eighteen new, non-executive employees.
By Iovance Biotherapeutics, Inc. · Via GlobeNewswire · September 18, 2026
Iovance Biotherapeutics to Present at Upcoming Conferences
SAN CARLOS, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following upcoming conferences:
By Iovance Biotherapeutics, Inc. · Via GlobeNewswire · September 4, 2026
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on August 20, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 240,135 shares of Iovance’s common stock to twenty new, non-executive employees.
By Iovance Biotherapeutics, Inc. · Via GlobeNewswire · August 21, 2026